GRIN1 and Stroke: Last, a body of research shows a similar NMDAR1-abs serum prevalence in other disease cohorts as well as in healthy subjects.[5, 6, 10, 27] We consider that preexisting serum NMDAR1-abs enter brain parenchyma as a consequence of stroke where they may downregulate NMDA receptors and hamper NMDAR function and functional recovery of the damaged tissue [23].